← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV14행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyLimited DatastalePhase 1
lorigerlimab (lorigerlimab)
MacroGenics·Advanced Solid Tumor
9 trials
Overview
Program
lorigerlimab
Overview
Company
MacroGenics
Overview
Modality
ANTIBODY
Overview
Target
Advanced Solid Tumor
Overview
Indication
Advanced Solid Tumor; Castration-Resistant Prostatic Cancer
Overview
Phase
PHASE_1
Overview
Status
ACTIVE
Overview
Content status
Limited Data
Overview
Data Confidence
Data Confidence · Low
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
Toxicology
Major finding
Bispecific Dual-Immune Checkpoint Inhibitor Associated Cutaneous Toxicity: A Report of Lorigerlimab Adverse Skin Reaction in Two Cancer Patients.. Lorigerlimab is a dual bispecific antibody (BsAb) targeting cytotoxic T-lymphocyte-associated protein 4 and programmed cell death protein 1 that is used for treatment of advanced solid cancers such as metastatic castration-resistant prostate carcinoma. …
Clinical
Safety signal
Bispecific Dual-Immune Checkpoint Inhibitor Associated Cutaneous Toxicity: A Report of Lorigerlimab Adverse Skin Reaction in Two Cancer Patients.. Lorigerlimab is a dual bispecific antibody (BsAb) targeting cytotoxic T-lymphocyte-associated protein 4 and programmed cell death protein 1 that is used for treatment of advanced solid cancers such as metastatic castration-resistant prostate carcinoma. …
Clinical
Program phase
PHASE_1
lorigerlimab 비교 | 바이오정보모아